The U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s oral heart disease drug, making Camzyos (mavacamten) the first cardiac myosin inhibitor to be permitted for use in the country.

A federal jury in Colorado awarded $383.5 million to the families of three patients who said they suffered cardiac arrests and died soon after receiving dialysis treatments at clinics run by DaVita Inc.

Black Americans are more likely to suffer sudden cardiac arrest than their white counterparts, a new study suggests. Black participants in the new study were also more likely to suffer cardiac arrest at a younger age than whites and to have known risk factors for heart disease, such as diabetes, high blood pressure and kidney […]